thrombocythemia

Updated: July 29, 2022

Background

Epidemiology

Anatomy

Pathophysiology

Etiology

Genetics

Prognostic Factors

Clinical History

Physical Examination

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

fedratinib

fedratinib treats adults with a high risk of thrombocythemia or polycythemia (myelofibrosis). The oral dose for the adult patient for the same is 400 mg four times daily.
If the baseline platelet count is more than 50 x 109/L: 400mg orally each day

Dose Adjustments

If unable to tolerate the dose of 200mg per day, discontinue the treatment
Co-administration with strong CYP3A4 inhibitors
Reduce the dose of fedratinib to 200 mg each day
If strong CYP3A4 inhibitors are discontinued, increase the dose of fedratinib to 300 mg daily
Discontinue the usage of CYP3A4 inhibitors for initial 2 weeks. Continue the dose later to 400 mg each day
In case of hematologic adverse reactions, restart the dose with 100 mg per day
In case of high-grade nausea, diarrhea, and vomiting, interrupt the dose until it is resolved to lower grade baseline. Restart from 100 mg per day below the last given dose
In case of high-grade hepatoxicity, discontinue the treatment

anagrelide

0.5 mg orally every 6 hour or 1 mg every 12 hour
enhance the dose as needed maximum up to 0.5 mg/day/week Not more than 2.5 mg/dose or 10 mg/day
Platelet count responds generally within 7 to 14 days; required completion time for action is 4 to 12 weeks

Future Trends